<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488954</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000835-34</org_study_id>
    <secondary_id>35RC14_9817_EMMENTAL</secondary_id>
    <nct_id>NCT02488954</nct_id>
  </id_info>
  <brief_title>Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis</brief_title>
  <acronym>EMMENTAL</acronym>
  <official_title>Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis (UC) is an immune mediated chronic inflammatory bowel disease that results&#xD;
      at least in part of an abnormal immune response to environmental factors including the&#xD;
      intestinal microbiota. Thus, use of probiotics (microorganisms that are believed to provide&#xD;
      health benefits when consume) may restore the gastrointestinal microbiota and reduce&#xD;
      intestinal inflammation.&#xD;
&#xD;
      Propionibacterium freudenreichii is used for the production of fermented food products&#xD;
      (cheese). Some selected strains have strong anti-inflammatory properties. Use of cheese based&#xD;
      on a monoxenic culture of anti-inflammatory strain of Propionibacterium freudenreichii may&#xD;
      decrease disease activity during ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties&#xD;
  </why_stopped>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Week 8</time_frame>
    <description>Response rate is defined by a decrease of at least two points of the Simple Clinical Colitis Index (SCCI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical response</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>Week 4</time_frame>
    <description>Clinical remission rate is defined by a SCCI&lt;3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical remission rate is defined by a SCCI&lt;3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mucosal healing</measure>
    <time_frame>Week 8</time_frame>
    <description>Mucosal Healing is defined by a Mayo endoscopic subscore of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of deep (clinical and endoscopic) remission</measure>
    <time_frame>Week 8</time_frame>
    <description>Deep remission is defined clinically and by endoscopic exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Week 8</time_frame>
    <description>Assessment of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response based on presence of Proprionibacterium freudenreichii in stools at week 0</measure>
    <time_frame>Week 8</time_frame>
    <description>Proprionibacterium freudenreichii analysis in stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate based on presence of Proprionibacterium freudenreichii in stools at week 0</measure>
    <time_frame>Week 8</time_frame>
    <description>Proprionibacterium freudenreichii analysis in stools</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotics in the form of cheese portion</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with age above 18 years old&#xD;
&#xD;
          -  Patient with diagnosis of ulcerative colitis for at least 6 months.&#xD;
&#xD;
          -  Patient with mayo endoscopic score â‰¥ 1&#xD;
&#xD;
          -  Patient with mild to moderate disease activity (3 &lt; SCCI &lt; 12)&#xD;
&#xD;
          -  Ongoing treatment by mesalamine, steroids, thiopurines or Tumor Necrosis Factor&#xD;
             antagonist at stable dose.&#xD;
&#xD;
          -  Patients who have given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults legally protected (under judicial protection, guardianship, or supervision),&#xD;
             persons deprived of their liberty.&#xD;
&#xD;
          -  Psychiatric disease that alter the judgment&#xD;
&#xD;
          -  Stoma&#xD;
&#xD;
          -  Proctocolectomy&#xD;
&#xD;
          -  Severe disease (SCCI &gt;12, acute severe colitis)&#xD;
&#xD;
          -  Steroid dose &gt; 10 mg/j or introduction of steroid (topic or oral) within 4 weeks&#xD;
&#xD;
          -  Introduction or dose optimization of TNF antagonist within 4 months&#xD;
&#xD;
          -  Introduction or dose optimization of thiopurine&#xD;
&#xD;
          -  Hemoglobin level &lt; 11,5 g/dL, Platelets &gt; 400000/mm3, Leukocytosis &gt; 10 000/mm3&#xD;
&#xD;
          -  Intolerant to lactose&#xD;
&#xD;
          -  Disease extent limited to the rectum&#xD;
&#xD;
          -  Mayo endoscopic subscore of 3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Probiotics</keyword>
  <keyword>treatments</keyword>
  <keyword>Propionibacterium freudenreichii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

